Name of the Procedure:
Fetal Congenital Abnormalities Screening, Biochemical Assays of Five Analytes (AFP, uE3, Total hCG, Hyperglycosylated hCG, DIA) Utilizing Maternal Serum
Summary
This procedure involves a blood test from a pregnant woman to assess the risk of certain fetal congenital abnormalities. The maternal serum is analyzed for five specific biochemical markers, and the results are used to generate a risk score.
Purpose
The procedure aims to identify the risk of congenital abnormalities in a fetus. By analyzing maternal serum, healthcare providers can estimate the likelihood of conditions such as Down syndrome, trisomy 18, and neural tube defects.
Indications
- Pregnant women, typically between 15 to 20 weeks of gestation
- Patients with increased risk factors for fetal abnormalities (e.g., advanced maternal age, family history)
- Screening as part of routine prenatal care
Preparation
- No specific preparations required
- Routine blood sample collection
- Patients may be advised to inform their healthcare provider of any medications or supplements they are taking
Procedure Description
- A blood sample is drawn from the patient's arm using a needle.
- The sample is sent to a laboratory where it is analyzed for five biochemical markers: Alpha-fetoprotein (AFP), unconjugated estriol (uE3), total human chorionic gonadotropin (hCG), hyperglycosylated hCG, and dimeric inhibin-A (DIA).
- The results of these assays are input into an algorithm that calculates a risk score for fetal congenital abnormalities.
Duration
The blood draw itself takes about 5-10 minutes. Results are typically available within a few days to a week.
Setting
The procedure is performed in an outpatient setting, such as a hospital, clinic, or doctor's office.
Personnel
- Phlebotomist or nurse to draw the blood sample
- Laboratory technicians to process and analyze the blood sample
- Obstetrician or maternal-fetal medicine specialist to interpret the results
Risks and Complications
- Minor discomfort or bruising at the blood draw site
- Rare risk of infection at the needle insertion site
- False-positive or false-negative results, necessitating further testing
Benefits
- Early identification of potential fetal congenital abnormalities
- Informed decision-making for expectant parents and healthcare providers
- Non-invasive and safe for both mother and fetus
Recovery
- No recovery time needed from the blood draw itself
- Patients can return to normal activities immediately
- Follow-up appointments for further testing or consultation if the risk score is elevated
Alternatives
- Detailed ultrasound (anomaly scan)
- Non-invasive prenatal testing (NIPT) for specific genetic conditions
- Invasive diagnostic tests such as amniocentesis or chorionic villus sampling (CVS)
- Pros and cons: Alternatives like NIPT are more specific but can be more costly. Invasive tests provide more definitive results but carry risks such as miscarriage.
Patient Experience
- The blood draw may cause slight discomfort or pain, similar to any routine blood test.
- Patients may feel anxious while waiting for results, but counseling and support are usually provided.
- Comfort measures include applying a warm compress to the draw site if bruising occurs and following up with healthcare providers for any concerns.